Novel Anti-Melanogenic Compounds, (Z)-5-(Substituted Benzylidene)-4-thioxothiazolidin-2-one Derivatives: In Vitro and In Silico Insights
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- MOLECULES26(16) · #4963 · 2021
- 피인용
- Web of Science 8Scopus 10
- FWCI (Scopus)
- 0.66
- JCR IF
- JCR 2020 4.412
- ISSN
- 1420-3049
저자
- 최희정제1저자Pusan Natl Univ, Coll Pharm, Med Chem Lab, Busan 46241, South Korea
- 유일영Pusan Natl Univ, Coll Pharm, Med Chem Lab, Busan 46241, South Korea
- 최인규Pusan Natl Univ, Coll Pharm, Med Chem Lab, Busan 46241, South Korea
- Ullah, SultanScripps Res Inst, Dept Mol Med, Jupiter, FL 33458 USA
- 정희진Pusan Natl Univ, Coll Pharm, Med Chem Lab, Busan 46241, South Korea
- 박유진Pusan Natl Univ, Coll Pharm, Med Chem Lab, Busan 46241, South Korea
- 정영무Pusan Natl Univ, Coll Pharm, Med Chem Lab, Busan 46241, South Korea
- 황예지Pusan Natl Univ, Coll Pharm, Med Chem Lab, Busan 46241, South Korea
- 홍소정Pusan Natl Univ, Coll Pharm, Med Chem Lab, Busan 46241, South Korea
- 윤인수Pusan Natl Univ, Coll Pharm, Med Chem Lab, Busan 46241, South Korea
- 윤화영Pusan Natl Univ, Coll Pharm, Med Chem Lab, Busan 46241, South Korea
- 김민수Pusan Natl Univ, Coll Pharm, Med Chem Lab, Busan 46241, South Korea
- 유진욱Pusan Natl Univ, Coll Pharm, Med Chem Lab, Busan 46241, South Korea
- 정연진Pusan Natl Univ, Coll Pharm, Med Chem Lab, Busan 46241, South Korea
- Chun, Pusoon교신저자Inje Univ, Coll Pharm, Gyeongnam 50834, Gimhae, South Korea
- 문형룡교신저자Pusan Natl Univ, Coll Pharm, Med Chem Lab, Busan 46241, South Korea
초록
To confirm that the beta-phenyl-alpha,beta-unsaturated thiocarbonyl (PUSTC) scaffold, similar to the beta-phenyl-alpha,beta-unsaturated carbonyl (PUSC) scaffold, acts as a core inhibitory structure for tyrosinase, twelve (Z)-5-(substituted benzylidene)-4-thioxothiazolidin-2-one ((Z)-BTTZ) derivatives were designed and synthesized. Seven of the twelve derivatives showed stronger inhibitory activity than kojic acid against mushroom tyrosinase. Compound 2b (IC50 = 0.47 +/- 0.97 mu M) exerted a 141-fold higher inhibitory potency than kojic acid. Kinetic studies' results confirmed that compounds 2b and 2f are competitive tyrosinase inhibitors, which was supported by high binding affinities with the active site of tyrosinase by docking simulation. Docking results using a human tyrosinase homology model indicated that 2b and 2f might potently inhibit human tyrosinase. In vitro assays of 2b and 2f were conducted using B16F10 melanoma cells. Compounds 2b and 2f significantly and concentration-dependently inhibited intracellular melanin contents, and the anti-melanogenic effects of 2b at 10 mu M and 2f at 25 mu M were considerably greater than the inhibitory effect of kojic acid at 25 mu M. Compounds 2b and 2f similarly inhibited cellular tyrosinase activity and melanin contents, indicating that the anti-melanogenic effects of both were due to tyrosinase inhibition. A strong binding affinity with the active site of tyrosinase and potent inhibitions of mushroom tyrosinase, cellular tyrosinase activity, and melanin generation in B16F10 cells indicates the PUSTC scaffold offers an attractive platform for the development of novel tyrosinase inhibitors.
키워드
tyrosinasePUSTC scaffoldanti-melanogenic effectdocking simulationBIOLOGICAL-ACTIVITIESMOLECULAR DOCKINGTYROSINASEINHIBITORSSKINANTICANCERMECHANISMRHODANINESCAFFOLDDESIGN
식별자
- Scopus EID
- 2-s2.0-85113508183
- WoS UID
- 000690172100001



로그인
연구물 목록으로